Merck 4Q Revenues: $10.5 billion (-7%) 4Q Earnings: $7.3 billion (earnings were $781 million 4Q13) FY Revenues: $42.2 billion (-4%) FY Earnings: $11.9 billion (earnings were $4.4 billion FY13) Comments: Pharmaceutical sales were down 4% to $9.4 billion in the quarter. Zetia/Vytorin, Remicade, and Gardasil sales were all down 10% to $1.0 billion, $557 million, and $356 million, respectively. Januvia sales were up 2% to $1.7 billion. Isentress sales were down 5% to $418 million. Nasonex sales...